Phosphorylation of FAK/PTK2 and its downstream effectors, P130Cas and paxillin, was reduced in defactinib-treated JIMT-1 and MDA-MB-231 breast cancer cell lines compared with DMSO-treated cells. This evidence concerns the gene PTK2 and breast carcinoma.